HIGHLIGHTS
- who: Erlinda Maria Gordon and colleagues from the Sarcoma Oncology Research Center, Santa Monica, CA, USA have published the Article: SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma, in the Journal: Cancers 2023, 15, 906. of 27/01/2023
- what: The study shows PD-1/PD-L1 expression in tumors was not associated with improved treatment outcome parameters.
- how: Ethical Statement This clinical trial was conducted in accordance with Good Clinical Practice (GCP) as required by . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.